We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
-6.59%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$41.7M
Cap. Flow
+$58.7M
Cap. Flow %
38.72%
Top 10 Hldgs %
53.82%
Holding
52
New
30
Increased
1
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$15.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$11.2M
3
SNY icon
Sanofi
SNY
+$10.2M
4
GSK icon
GSK
GSK
+$9.66M
5
AMRN
Amarin Corp
AMRN
+$8.53M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$10.1M
2
COGT icon
Cogent Biosciences
COGT
+$8.96M
3
LNTH icon
Lantheus
LNTH
+$7.59M
4
GH icon
Guardant Health
GH
+$6.45M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.25M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNCE
26
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.04M 1.35%
63,326
-7,182
-10% -$266K
WHWK
27
Whitehawk Therapeutics
WHWK
$188M
$1.76M 1.16%
+124,625
New +$1.64M
NAUT icon
28
Nautilus Biotechnolgy
NAUT
$220M
$1.75M 1.15%
823,974
-256,592
-24% -$645K
INCY icon
29
Incyte
INCY
$23.5B
$1.67M 1.1%
+25,000
New +$1.85M
ICPT
30
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.4M 0.92%
+100,000
New +$1.61M
NKTR icon
31
Nektar Therapeutics
NKTR
$2.41B
$1.39M 0.91%
+28,863
New +$1.72M
VOR icon
32
Vor Biopharma
VOR
$1.04B
$1.02M 0.67%
+12,758
New +$1.25M
EDIT icon
33
Editas Medicine
EDIT
$410M
$1.01M 0.67%
+82,900
New +$1.29M
CLVS
34
DELISTED
Clovis Oncology, Inc.
CLVS
$635K 0.42%
+533,501
New +$832K
RNAC icon
35
Cartesian Therapeutics
RNAC
$233M
$548K 0.36%
+11,142
New +$612K
MOR
36
DELISTED
MorphoSys AG American Depositary Shares
MOR
$478K 0.32%
+95,031
New +$491K
CRIS icon
37
Curis
CRIS
$10M
$185K 0.12%
+660
New +$266K
PBYI icon
38
Puma Biotechnology
PBYI
$411M
$152K 0.1%
+64,295
New +$188K
INFI
39
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$103K 0.07%
+86,242
New +$93K
FATE icon
40
Fate Therapeutics
FATE
$289M
– –
-181,500
Closed -$4.5M
GH icon
41
Guardant Health
GH
$19.7B
– –
-160,000
Closed -$6.45M
LNTH icon
42
Lantheus
LNTH
$6.85B
– –
-115,000
Closed -$7.59M
NUVB icon
43
Nuvation Bio
NUVB
$2.24B
– –
-1,137,152
Closed -$3.68M
RLMD icon
44
Relmada Therapeutics
RLMD
$540M
– –
-160,000
Closed -$3.04M
STOK icon
45
Stoke Therapeutics
STOK
$1.84B
– –
-175,000
Closed -$2.31M
VRDN icon
46
Viridian Therapeutics
VRDN
$2.14B
– –
-496,012
Closed -$5.74M
CERE
47
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-170,000
Closed -$4.5M
SLGC
48
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-735,000
Closed -$3.32M
KDNY
49
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-250,000
Closed -$4.37M
DICE
50
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-207,290
Closed -$3.22M
1
2
3

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q3 2022 Portfolio in Review

As of Q3 2022, Ally Bridge Group held 52 positions worth $151M, up 38% from $110M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ally Bridge Group deployed $58.7M of net new capital in Q3 2022, opening 30 new positions and adding to 1 existing holding. Its largest new stake was Seagen Inc. Common Stock: 92,506 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $10.1M trimmed.

  • Ally Bridge Group's largest Q3 2022 buy was Seagen Inc. Common Stock: 92,506 shares worth $12.7M.
  • Ally Bridge Group added most to Syros Pharmaceuticals, Inc. Common Stock in Q3 2022, an estimated $4.32M increase.
  • Ally Bridge Group's biggest Q3 2022 reduction was argenx, cutting an estimated $10.1M.
  • Ally Bridge Group fully exited Lantheus in Q3 2022, selling an estimated $7.59M.
  • Ally Bridge Group's ten largest holdings make up 54% of its $151M portfolio in Q3 2022.
  • Ally Bridge Group opened 30 new positions and closed 13 in Q3 2022.
  • Ally Bridge Group's portfolio value rose 38% quarter-over-quarter to $151M.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.